Koshinski Asset Management
IMDX

Koshinski Asset Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Koshinski Asset Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-110
Closed -$3.28K – 1513
2022
Q1 		$3.28K Hold
110
– – ﹤0.01% 1870
2021
Q4 		$4.77K Sell
110
-50
-31% -$2.88K ﹤0.01% 1816
2021
Q3 		$11.4K Buy
+160
New +$14.7K ﹤0.01% 1620

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Koshinski Asset Management's IMDX Position: Q2 2022 in Review

Koshinski Asset Management sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 110 shares — an estimated $3.28K sold.

Koshinski Asset Management first reported a position in IMDX in Q3 2021 and held it in 3 quarters. The position peaked at $11.4K in Q3 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Koshinski Asset Management reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 110 Insight Molecular Diagnostics shares in Q2 2022, an estimated $3.28K.
  • Koshinski Asset Management first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's Insight Molecular Diagnostics position peaked at $11.4K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.